G Kourlaba’s research while affiliated with University of Peloponnese and other places

... The add-on treatment with CoV-2-STs was well tolerated and increased the likelihood of recovery by day 30, shortened the time to recovery and lowered by 51% the risk of mortality than SoC-alone, suggesting that the off-the-shelf immunotherapy with CoV-2-STs can serve as a safe and effective treatment in a real-world environment for severe COVID-19. 79 To optimize CoV-2-ST performance in the presence of immunosuppressants which are used for the management of severe COVID-19, genetically modified CoV-2-STs resistant to glucocorticoids 186 or tacrolimus 187 have also been proposed (Table 1). ...

Reference:

Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond

... The selected studies were CEA (n = 70) 18-29,31-37,39-47, 49-55,58,59,61-63,65-72,74,75,78-89,91-97,99 and cost-utility analyses (n = 13). 30,38,48,56,57,60,64,73,76,77,81,90 Most studies were conducted from a public payer perspective (91.6%), 6% from a societal perspective, and 2.4% had not specified (NS) their perspective. QALYs were used as the effectiveness measure in 56 studies (67.5%), whereas 22 studies (26.5%) used both QALYs and LYs to measure the effectiveness of each treatment compared with others. ...

Reference:

Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece

... For chemotherapy, it was derived from a retrospective study measuring the initial treatment costs for LC patients [38]. For the immunotherapy and targeted therapy, unit costs per course were synthesized based on the treatment scheme recommended by the Guidelines of the Hellenic Society of Medical Oncologists (HESMO) [44], and the average weighted costs per medication were estimated based on the price per package [37] and the median treatment duration [45][46][47][48][49]. Details for this micro-costing synthesis can be found in Tables D and F in S1 File. ...

Reference:

Lung cancer screening with volume computed tomography is cost-effective in Greece

... Possible sepsis was considered in cases with elevated inflammatory markers but negative cultures and a reassuring clinical condition. A central-line-associated bloodstream infection (CLABSI) was defined as the isolation of a pathogen from the blood culture of neonates with a central line at the time of infection or within the previous 48 h [62]. ...

Reference:

Elimination of Candida Sepsis and Reducing Several Morbidities in a Tertiary NICU in Greece After Changing Antibiotic, Ventilation, and Nutrition Protocols

... More recently, PGT has been applied to polygenic diseases, also sharing the goal of a healthy pregnancy and birth, a practice that has raised ethical and scientific concerns about its efficacy [31,32]. In the case of haemoglobinopathies, PGT has a valuable role in preventing genetic disease in offspring of carrier parents, avoiding pregnancy termi-nation, and enabling treatment of an existing affected child with thalassemia or SCD by selecting a compatible sibling donor for potential future stem cell transplantation (PGT for HLA-typing) [33,34]. ...

Reference:

Reproductive Choices in Haemoglobinopathies: The Role of Preimplantation Genetic Testing

... QALYs were used as the effectiveness measure in 56 studies (67.5%), whereas 22 studies (26.5%) used both QALYs and LYs to measure the effectiveness of each treatment compared with others. The Psoriasis Area and Severity Index (n = 1), 80 LYs (n = 2), 33,34 LY/event avoided (n = 1), 28 and events avoided (n = 1) 89 were also included as effectiveness measures ( ...

Reference:

Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece

... Our cost-utility analysis was conducted using a five-state Markov model including event free, locoregional recurrence, metastasis, remission, and death (Fig. 1). The model was developed considering the six-state model commonly used in previous economic evaluation studies 25,[34][35][36] , and was verified with clinical expert opinion based on the current practice in Sri Lanka. Although the treatment cycle length of neoadjuvant therapy strategies is 3 weeks, the cycle length used in our model was 1 month to be able to capture the effect of treatment. ...

Reference:

Cost-utility and budget impact analysis of neoadjuvant dual HER2 targeted therapy for HER2-positive breast cancer in Sri Lanka

... Of 193 publications returned from the search, 18 cost-effectiveness studies met the inclusion criteria ( Fig. 1) [16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33]. Five of the 18 studies were published as full-text articles [17,19,22,26,33] and the remaining were abstracts presented at conferences. ...

Reference:

A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer

... The selected studies were CEA (n = 70) 18-29,31-37,39-47, 49-55,58,59,61-63,65-72,74,75,78-89,91-97,99 and cost-utility analyses (n = 13). 30,38,48,56,57,60,64,73,76,77,81,90 Most studies were conducted from a public payer perspective (91.6%), 6% from a societal perspective, and 2.4% had not specified (NS) their perspective. QALYs were used as the effectiveness measure in 56 studies (67.5%), whereas 22 studies (26.5%) used both QALYs and LYs to measure the effectiveness of each treatment compared with others. ...

Reference:

Does a Standard Cost-Effectiveness Threshold Exist? The Case of Greece

... The role of government intervention in pricing transparency, rebate structuring, and market competition will be analyzed to determine the feasibility of large-scale adoption of hybrid pricing models [22]. By integrating insights from multiple disciplines, this study aims to provide a comprehensive framework for developing cost-effective, patient-centric pharmaceutical pricing strategies that enhance accessibility and adherence while preserving financial sustainability within the healthcare sector [23]. ...

Reference:

Corresponding author: Tolulope O Jagun Integrating dynamic pricing models with pharmacy benefit manager strategies to enhance medication affordability and patient adherence